How This Evidence Evolved
Vasopressor Selection in Septic Shock
Beyond the dopamine era
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
28-day mortality 52.5% vs 48.5%, p=0.10; arrhythmias 24.1% vs 12.4%, p<0.001
28-day mortality (or closest estimate) in randomised trials: dopamine vs norepinephrine RR 1.12 (CI 1.01-1.20; p=.035); arrhythmias (2 trials): RR 2.34 (CI 1.46-3.77; p=.001)
Follow-up studies, subgroup analyses, and real-world validation
MAP response at hour 3: 69.9% vs 23.4%, p<0.001
Kidney failure-free days: no significant difference; RRT: vasopressin 25.4% vs norepinephrine 35.3%
Death or severe complications (stroke, ventilation >48 h, deep sternal wound infection, reoperation or acute renal failure) within 30 days: vasopressin 32% (n=149) vs norepinephrine 49% (n=151) (unadjusted HR 0.55, 95% CI 0.38-0.80; P=0.0014)
Integration into clinical practice guidelines and recommendations
Norepinephrine first-line (strong); add vasopressin for inadequate MAP rather than escalating norepinephrine (weak).
Suggest adding vasopressin rather than escalating norepinephrine for inadequate MAP (weak recommendation); vasopressin is usually fixed at 0.03 U/min.
Do not use low-dose dopamine to prevent or treat AKI (1A).
Current standard of care and ongoing research directions
Ventilator- and vasopressor-free days within 30 days: combination 25 vs placebo 26 days (median difference -1 day, 95% CI -4 to 2; P=.85).
Time alive and free of vasopressors to day 7: combination 122.1 h vs hydrocortisone alone 124.6 h; paired median difference −0.6 h (95% CI −8.3 to 7.2; P=.83).
Landmark Trials in This Story
Vasopressin versus norepinephrine infusion in patients with septic shock
28-day mortality 35.4% vs 39.3%, p=0.26
Comparison of dopamine and norepinephrine in the treatment of shock
28-day mortality 52.5% vs 48.5%, p=0.10; arrhythmias 24.1% vs 12.4%, p<0.001
Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis.
28-day mortality (or closest estimate) in randomised trials: dopamine vs norepinephrine RR 1.12 (CI 1.01-1.20; p=.035); arrhythmias (2 trials): RR 2.34 (CI 1.46-3.77; p=.001)
Angiotensin II for the Treatment of Vasodilatory Shock
MAP response at hour 3: 69.9% vs 23.4%, p<0.001
Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial
Kidney failure-free days: no significant difference; RRT: vasopressin 25.4% vs norepinephrine 35.3%
Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.
Death or severe complications (stroke, ventilation >48 h, deep sternal wound infection, reoperation or acute renal failure) within 30 days: vasopressin 32% (n=149) vs norepinephrine 49% (n=151) (unadjusted HR 0.55, 95% CI 0.38-0.80; P=0.0014)
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.
Ventilator- and vasopressor-free days within 30 days: combination 25 vs placebo 26 days (median difference -1 day, 95% CI -4 to 2; P=.85).
Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.
Time alive and free of vasopressors to day 7: combination 122.1 h vs hydrocortisone alone 124.6 h; paired median difference −0.6 h (95% CI −8.3 to 7.2; P=.83).
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.